mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2024-08-14
Target enrollment:
Participant gender:
Summary
Modified FOLFIRINOX (mFOLFIRINOX) is the standard of care for patients with locally advanced
pancreatic adenocarcinoma. While radiotherapy has been investigated for the management of
resectable or locally advanced pancreatic adenocarcinoma, its role in the era of modern
chemotherapy is not clear. Stereotactic body radiotherapy (SBRT) is the novel technique of
radiotherapy to enhance the dose of radiotherapy to the target tumor lesion. This trial aims
to compare the efficacy and safety of mFOLFIRINOX with or without SBRT in patients with
locally advanced pancreatic adenocarcinoma